

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/872.733
		Filing Date	June 1, 2001
		First Named Inventor	George N. Pavlakis
		Art Unit	1632 / 1648
		Examiner Name	Dave Trong Nguyen
		Attorney Docket Number	015280-257100US
Sheet	1	of	1

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
NC	GA	NGO et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox." <i>The Protein Folding Problem and Tertiary Structure Prediction</i> , K. Merz, Jr. and S. Le Grand, Editors (1994) pages 491-495	

NC - Refer was not considered.

Examiner Signature		Date Considered	01/21/07
-----------------------	--	--------------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Unsaved Document

FORM PTO-1449 INFORMATION DISCLOSURE CITATION		Attorney Docket:	Serial No.:
		2026-4287US1	09/872,733
		Applicant:	
		George Pavlakakis	
		Filing Date:	Group Art Unit:
		June 1, 2001	2635 1648

U.S. PATENT DOCUMENTS						
Examiner Initial	Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Patent Number	Issue Date	Country	Class	Sub-Class	Translation
NC	WO 98/17816	April 30, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/46082	October 22, 1998	PCT			
	WO 99/04026	January 28, 1999	PCT			
	WO 99/15641	April 1, 1999	PCT			
	WO 99/30742	June 24, 1999	PCT			
	WO 99/51754	October 14, 1999	PCT			
	WO 00/65076	November 2, 2000	PCT			

OTHER DOCUMENTS (continued)	
NC	Akkina, R.K. et al., "High-Efficiency Gene Transfer into CD34+ Cells with a Human Immunodeficiency Virus Type 1-Based Retroviral Vector Pseudotyped with Vesicular Stomatitis Virus Envelope Glycoprotein G", J. Virology, 70:2581-2585 (1996)
	Amado, R.G. et al., "Lentiviral Vectors - the Promise of Gene Therapy Within Reach?", Science, 285:674-676 (July 1999)
	Donahue, R.E. et al., "Transplantation of Immunoselected CD34+ Cells Transduced with a EGFP-Expressing Lentiviral Vector in Non-Human Primates", Blood, 92 (Suppl. 1):383b, Abstract #4648.5 (1998)
	Fox, J.L., "Researchers wary of fear-based ban on lentivirus gene therapy", Nature Biotechnology, 16:407-408 (1998)
	Goldman, M.J. et al., "Lentiviral Vectors for Gene Therapy of Cystic Fibrosis", Human Gene Therapy, 8:2261-2268 (1997)
	Kafri, T. et al., "Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors", Nature Genetics, 17:314-317 (1997)
	Kafri, T. et al., "A Packaging Cell Line for Lentivirus Vectors", J. Virol., 73:576-584 (1999)
	Kim, V.N. et al., "Minimal Requirement for a Lentivirus Vector Based on Human Immunodeficiency Virus Type 1", J. Virol., 72:811-816 (1998)
	Klimatcheva, E. et al., "Lentiviral Vectors and Gene Therapy", Frontiers in Bioscience, 4:d481-496 (June 1999)
	Kotsopoulou, E. et al., "A Rev-Independent Human Immunodeficiency Virus Type 1 (HIV-1)-Based Vector That Exploits a Codon-Optimized HIV-1 gag-pol Gene", J. Virol., 74:4839-4852 (2000)
	Miyoshi, H. et al., "Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector", Proc. Natl. Acad. Sci. USA, 94:10319-10323 (1997)

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	01/27/07

NC - reference was not considered.

FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakis	
	Filing Date: June 1, 2001	Group Art Unit: 1633 1648

OTHER DOCUMENTS (continued)	
NC	Miyoshi, H. et al., "Development of a Self-Inactivating Lentivirus Vector", J. Virol., 72:8150-8157 (1998)
	Miyoshi, H. et al., "Transduction of Human CD34 ⁺ Cells That Mediate Long-Term Engraftment of NOD/SCID Mice by HIV Vectors", Science, 283:682-686 (1999)
	Naldini, L. et al., "In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector", Science, 272:263-267 (1996)
	Naviaux, R.K. et al., "The pCL Vector System: Rapid Production of Helper-Free, High-Titer, Recombinant Retroviruses", J. Virol., 70:5701-5705 (1996)
	Poeschla, E.M. et al., "Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors", Nature Med., 4:354-357 (1998)
	Reynolds, P.N. et al., "Viral vectors show promise in Colorado", Nature Biotechnology, 16:422-423 (1998)
	Soneoka, Y. et al., "A transient three-plasmid expression system for the production of high titer retroviral vectors", Nuc. Acids Res., 23:628-633 (1995)
	Srinivasakumar, N. et al., "The Effect of Viral Regulatory Protein Expression on Gene Delivery by Human Immunodeficiency Virus Type 1 Vectors Produced in Stable Packaging Cell Lines", J. Virol., 71:5841-5848 (1997)
	Sutton, R.E. et al., "Human Immunodeficiency Virus Type 1 Vectors Efficiently Transduce Human Hematopoietic Stem Cells", J. Virol., 72:5781-5788 (1998)
	Takahashi, M. et al., "Rescue from Photoreceptor Degeneration in the <i>rd</i> Mouse by Human Immunodeficiency Virus Vector-Mediated Gene Transfer", J. Virol., 73:7812-7816 (September 1999)
	Uchida, N. et al., "HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G ₀ /G ₁ human hematopoietic stem cells", Proc. Natl. Acad. Sci. USA, 95:11939-11944 (1998)
	Vinner, L. et al., "Gene gun DNA vaccination with Rev-independent synthetic HIV-1 gp160 envelope gene using mammalian codons", Vaccine, 17:2166-2175 (1999)
	Wagner, R. et al., "Rev-Independent Expression of Synthetic <i>gag-pol</i> Genes of Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus: Implications for the Safety of Lentiviral Vectors", Human Gene Therapy, 11:2403-2413 (2000)
	White, S.M. et al., "Lentivirus Vectors Using Human and Simian Immunodeficiency Virus Elements", J. Virol., 73:2832-2840 (1999)
	Wolff, J.A. et al., "The Cambrian period of nonviral gene delivery", Nature Biotechnology, 16:421-422 (1998)
	Zufferey, R. et al., "Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo", Nature Biotechnology, 15:871-875 (1997)
	Zufferey, R. et al., "Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery", 72:9873-9880 (1998)
Examiner	Date Considered 01/21/01
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

NC - Refs are not considered

FORM PTO-1449 INFORMATION DISCLOSURE CITATION		Attorney Docket: 2026-4287US1	Serial No.: 09/872,733			
		Applicant: George Pavlakis				
		Filing Date: June 1, 2001	Group Art Unit: To Be Assigned 1648			
U.S. PATENT DOCUMENTS						
Examiner Initial	Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date
J ↓	6,174,666 B1	Jan 16, 2001	Pavlakis and Felber			3/27/92
	5,972,596	Oct 29, 1999	Pavlakis and Felber			1994
	5,965,726	Oct 12, 1999	Pavlakis and Felber			5/2/97
	5,786,464	Jul 28, 1998	Seed and Haas			7/28/98
	5,795,737	Aug 18, 1998	Seed			9/22/95
	6,114,148	Sep 05, 2000	Seed and Haas			

FOREIGN PATENT DOCUMENTS						
Examiner Initial	Patent Number	Issue Date	Country	Class	Sub-Class	Translation
NC ↓	WO 90/11092	Oct. 1990	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 93/20212	Oct 14, 1993	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 96/09378	Mar 28, 1996	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 97/11086	Mar 27, 1997	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/2207	Mar 26, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 98/34640	Aug 11, 1998	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39302	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39303	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 00/39304	Jul 6, 2000	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/61596	Dec. 2, 1999	PCT			<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (continued)	
NC ↓	Nappi F, Schneider R, Zolotukhin A, Smulevitch S, Michalowski D, Bear J, Felber BK, and Pavlakis GN. "Identification of a Novel Posttranscriptional Regulatory Element by Using a rev- and RRE-Mutated Human Immunodeficiency Virus Type 1 DNA Proviral Clone as a Molecular Trap." J Virol. 2001 May;75(10):4558-69.
	Qiu JT, Liu B, Tian C, Pavlakis GN, Yu XF. "Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 gag by using DNA expression vectors that target Gag antigen to the secretory pathway." J Virol. 2000 Jul;74(13):5997-6005.
	Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK, Pavlakis GN, Yu XF. "Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses." J Virol. 1999 Nov;73(11):9145-52.

Examiner	Date Considered
J	01/21/07
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	

NC - references are not considered.

FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakis	
	Filing Date: June 1, 2001	Group Art Unit: To Be Assigned 1648

OTHER DOCUMENTS (continued)	
NC	Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. "Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation." J Virol. 1997 Jul;71(7):4892-903.
	Afonina E, Neumann M, Pavlakis GN. "Preferential binding of poly(A)-binding protein 1 to an inhibitory RNA element in the human immunodeficiency virus type 1 gag mRNA." J Biol Chem. 1997 Jan 24;272(4):2307-11.
	Schwartz S, Campbell M, Nasioulas G, Harrison J, Felber BK, Pavlakis GN. "Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression." J Virol. 1992 Dec.; 66(12):7176-82.
	Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. "Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage." J Virol. 1998 Feb; 72(2):1497-503.
	Haas J, Park EC, Seed B. "Codon usage limitation in the expression of HIV-1 envelope glycoprotein." Curr Biol. 1996 Mar 1;6(3):315-24.
	Ikemura, T. "Codon Usage and tRNA Content in Unicellular and Multicellular Organisms." Mol. Biol. Evol. 2(1):13-34 (1985)
	T. Maruyama et al., "Codon usage tabulated from the GenBank genetic sequence data", Nucl. Acids Res. 14:r151-r197 (1986)
	S. Aota et al., "Codon usage tabulated from the GenBank genetic sequence data", Nucl. Acids Res. 16:r315-r402 (1988)
	Shiver, et al., "DNA Vaccine-Mediated Cellular Immunity Against HIV-1 gag And env," abstract from the Conference on Advances in aids Vaccine Development; 8th Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS (NCVDGs), February 11-15, 1996
	Albert B Sabin, "Improbability of effective vaccination against human immunodeficiency virus because of its intracellular transmission and rectal portal of entry", Proc. Natl. Acad. Sci. USA, 89:8852-8855 (September 1992) ("Reference 1")
	Saladin Osmanov et al., "HIV-1 Genetic Variability: Implications for the Development of HIV Vaccines", Antibiotics and Chemotherapy, 48:30-38 (1996) ("Reference 2")
	Kavita S. Lole, et al., "Full-Length Human Immunodeficiency Virus Type 1 Genomes from Subtype C-Infected Seroconverters in India, with Evidence of Intersubtype Recombination", Journal of Virology, 73:152-160 (January 1999) ("Reference 3")
	"Nikkei Biotechnology Annual Report '98", Ed. NIKKEI BIOTECH, (Nov. 30, 1997), Nikkei Business Publications, Inc., p. 214 (English translation of table on page 214, lines 30-35 entitled "The recent stream of research and development on AIDS") ("Reference 4")
	R.I. Connor, et al., "Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit Vaccines", Journal of Virology, 72:1552-1576 (February 1998) ("Reference 5")
	"Nikkei Biotechnology Annual Report '97", Ed. NIKKEI BIOTECH, (Nov. 30, 1996), Nikkei Business Publications, Inc., p. 246 (English translation of a table on page 246, lines 43-46 entitled "The recent stream of biotechnological research on AIDS") ("Reference 6")

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	9/21/01

619029 v1

NC - reference was not considered.

FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attorney Docket: 2026-4287US1	Serial No.: 09/872,733
	Applicant: George Pavlakis	
	Filing Date: June 1, 2001	Group Art Unit: To Be Assigned 1648

OTHER DOCUMENTS (continued)	
NC	Nikkei Biotechnology Annual Report '99", Ed. NIKKEI BIOTECH, (Nov. 30, 1998), Nikkei Business Publications, Inc., p. 79 (English translation of table on p. 79, lines 14-17 entitled "The main stream of research and development on AIDS") ("Reference 7")
	Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner PL, Dwarki VJ, Gromkowski SH, Deck BK, DeWitt CM, Friedman A, Hawe LA, Leander KR, Martinez D, Perry HC, Shiver JW, Montgomery DL, Liu MA. "Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein." <i>Science</i> 259:1745-1748 (March 19, 1993)
	Afonina E., Stauber R., Pavlakis GN. "The Human Poly(A)-binding Protein 1 Shuttles between the Nucleus and the Cytoplasm", <i>The Journal of Biological Chemistry</i> , 273:13015-13021 (May 22, 1998)
	Solomin L., Felber BK., Pavlakis GN. "Different Sites of Interaction for Rev, Rev, and Rex Proteins within the Rev-Responsive Element of Human Immunodeficiency Virus Type 1", <i>Journal of Virology</i> , 64:6010-6017 (Dec. 1990)
	Benko DM., Robinson R., Solomin L., Mellini M., Felber BK., Pavlakis GN. "Binding of Trans-Dominant Mutant Rev Protein of Human Immunodeficiency Virus Type 1 to the Cis-Acting Rev-Responsive Element Does Not Affect the Fate of Viral mRNA", <i>The New Biologist</i> , 2:1111-1122 (Dec. 1990)
	Schwartz S., Felber BK., Pavlakis GN., "Distinct RNA Sequences in the gag Region of Human Immunodeficiency Virus Type 1 Decrease RNA Stability and Inhibit Expression in the Absence of Rev Protein", <i>Journal of Virology</i> , 66:150-159 (Jan. 1992)
	D'Agostino DM., Felber BK., Harrison JE., Pavlakis GN. "The Rev Protein of Human Immunodeficiency Virus Type 1 Promotes Polysomal Association and Translation of gag/pol and vpu/env mRNAs", <i>Molecular and Cellular Biology</i> , 12:1375-1386 (March 1992)
	Myers G., Pavlakis GN. "Evolutionary Potential of Complex Retroviruses", <i>The Retroviridae</i> , 1:51-105 (1992)
	Zolotukhin AS., Valentin A., Pavlakis GN., Felber BK. "Continuous Propagation of RRE(+) and Rev(+)RRE(+) Human Immunodeficiency Virus Type 1 Molecular Clones Containing a cis-Acting Element of Simian Retrovirus Type 1 in Human Peripheral Blood Lymphocytes", <i>Journal of Virology</i> , 68:7944-7952 (Dec. 1994)
	Tan W., Felber BK., Zolotukhin AS., Pavlakis GN., Schwartz S. "Efficient Expression of the Human Papillomavirus Type 16 L1 Protein in Epithelial Cells by Using Rev and the Rev-Responsive Element of Human Immunodeficiency Virus or the cis-Acting Transactivation Element of Simian Retrovirus Type 1", <i>Journal of Virology</i> , 69:5607-5620 (Sept. 1995)
	Wolff JA., Malone RW., Williams P., Chong W., Acsadi G., Jani A., Felgner PL. "Direct Gene Transfer into Mouse Muscle in Vivo" <i>Science</i> , 247:1465-1468 (March 23, 1990)
	Wolff JA., Ludtke JJ., Acsadi G., Williams P., Jani A. "Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle", <i>Human Molecular Genetics</i> , 1(6):363-369 (1992)
	Egan MA., Charini WA., Kuroda MJ., Schmitz JE., Racz P., Tenner-Racz K., Manson K., Wyand M., Lifton MA., Nickerson CE., Fu T., Shiver JW., Letvin NL. "Simian Immunodeficiency Virus (SIV) gag DNA-Vaccinated Rhesus Monkeys Develop Secondary Cytotoxic T-Lymphocyte Responses and Control Viral Replication after Pathogenic SIV Infection" <i>Journal of Virology</i> , 74(16):7485-7495 (Aug. 2000)

Examiner	Date Considered
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	09/21/07

619029 v1

NC - Refer are not considered.